Importantly, nutraceuticals are an inexpensive and effective option that could be potentially used to prevent neuroinflammation, hence delaying the onset of AD, specifically for APOE4-carriers, who are at a higher risk of both AD and non-AD APOE4-associated neuroinflammatory processes, including recovery from head injury, cerebral haemorrhage, stroke and cerebral artery amyloidosis. This evidence concerns the gene APOE and Stroke.